key: cord-0882596-b8ef0en8
authors: Ondoa, Pascale; Ndlovu, Nqobile; Keita, Mah-Sere; Massinga-Loembe, Marguerite; Kebede, Yenew; Odhiambo, Collins; Mekonen, Teferi; Ashenafi, Aytenew; Kebede, Amha; Nkengasong, John
title: Preparing national tiered laboratory systems and networks to advance diagnostics in Africa and meet the continent’s health agenda: Insights into priority areas for improvement
date: 2020-09-21
journal: Afr J Lab Med
DOI: 10.4102/ajlm.v9i2.1103
sha: 5804592dee7a7a11b1360973663c9f590f832922
doc_id: 882596
cord_uid: b8ef0en8

nan

Access to diagnostics remains sub-optimal in Africa due to limited human, financial and technical resources that affect various components of the health system. 1, 2 Additionally, the lack of standardised systems for evaluation and registration of diagnostics 3 cripples the introduction of better technologies, representing missed opportunities to address healthcare challenges. Examples of poor access to diagnostics and its dramatic consequences are numerous. Despite strong vertical control programmes, 40% of HIV-infected patients on antiretroviral therapy do not receive the recommended yearly HIV viral load monitoring test. 4 In 2016, a dramatic 21% of children born to HIV-positive mothers were reported as not receiving early infant diagnosis testing before age 8 weeks in West and Central Africa. 5 Data from the World Health Organization (WHO) global tuberculosis database of 2016 6 also indicate that drug-resistant tuberculosis is largely missed in Africa. In addition to 70% of patients not being notified, a rifampicin susceptibility test was available to less than 10% of patients in 23 of 47 countries and second-line resistance testing was available only in 60% of the countries on the continent. 7 The picture is equally worrisome for diseases that are poorly or not supported through dedicated programmes. Nine in 10 individuals carrying the hepatitis B or C virus have never been tested, while these infections are estimated to cause 60% of liver cancers and an epidemic larger than that caused by HIV. 8 In a study conducted in Senegal in 2015-2016, less than 30% of pregnant women attending antenatal care at the primary healthcare level had access to the minimum panel of screening tests for the most common clinical conditions threatening maternal and child health. 9 Almost half of the mortality cases associated with cervical cancer are due to late detection of the disease. 10 More recently, it appeared that when the first coronavirus disease 2019 (COVID- 19) case was reported in Egypt in February 2020, only 2 of the 55 countries on the continent were capable of detecting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Insufficient access to in vitro diagnostics (IVD) at all levels of healthcare delivery in low-income and middle-income countries reduces access to life-saving treatments, impairs the delivery of quality healthcare and compromises progress towards Universal Health Coverage in Africa. Implementation of simplified, more robust and more affordable diagnostic options has been proposed to increase access to diagnostics in low-resource settings. Rapid diagnostic tests that can be performed at the community level or through self-testing have transformed the management and prevention of several diseases such as HIV infection, malaria and diabetes. 11, 12, 13 Point-of-care molecular technologies, such as the GeneXpert® or the m-Pima®, have been demonstrated to increase specificity and simplicity of testing, while reducing the turnaround time for test results 14, 15 for improved patient retention and management. Despite addressing critical testing processes or delivery gaps, innovative or conventional diagnostic technologies frequently fail to translate into tangible public health outcomes. 16, 17, 18 The failure of diagnostics to reach a large proportion of the population in need of it can partly be linked to implementation approaches that are designed for the site level, with oversight of the tiered laboratory network requirements and insufficient attention given to the underlying laboratory systems (e.g. supply chain, workforce, finance, etc.). Complementing the Maputo Declaration of 2008, 19 the Freetown Declaration of 2015 20 underscores that delivering diagnostic services in the context of functional, integrated national laboratory networks is the recommended strategy for providing maximum population coverage and cost-effective utilisation and delivery of diagnostic services in resource-limited settings.

Apart from selected disease-dedicated investments (e.g. HIV, tuberculosis), national tiered laboratory networks generally remain grossly underfunded with mild to critical dysfunctions in the underlying laboratory systems. In addition to falling short in the provision of optimal access to essential clinical diagnostics, the current sub-optimal capacity of tiered laboratory networks translates into weaknesses in the detection component of the 'prevent, detect, respond' framework of health security 21, 22 Missed opportunities to stop onward transmission of infectious diseases and to detect and prevent non-communicable diseases hinder efforts to reduce the burden of illnesses in Africa. The WHO estimates that the resulting loss of annual productivity due to the heavy disease burden in Africa equalled $2.4 trillion and 630 million years of healthy lives in 2015. 23 Despite the call for more attention in building effective public health laboratory systems, 24 which was made in the aftermath of the Ebola epidemic of 2015, few data exist that allow quantification of the overall performance of national laboratory networks and systems across diseases. This lack of information prevents the design of impactful interventions and hinders the uptake of the otherwise large and relevant range of diagnostic technologies available.

In this report, the African Society for Laboratory Medicine (ASLM) and the Africa Centres for Disease Control and Prevention (Africa CDC) share a unique insight into some of the most critical areas for improvement to bridge the gap between the capacity of laboratory networks and the promises of diagnostic technologies.

Actionable data on integrated laboratory network functionality are scarce. The WHO Joint External Evaluation 25 tool provides a high-level overview of the performance of the national laboratory network across four domains: (D1.1) laboratory testing for the detection of priority diseases, (D1.2) specimen referral and transport system, (D1.3) effective national diagnostic network and (D1.4) Laboratory Quality System, as part of the evaluation of entire national health systems to support compliance with International Health Regulations requirements. Data from 54 countries 21 indicate that quality management and sample referral systems are the most neglected areas across the continent with 68.1% and 50.0% of countries having none to only a basic capacity in place (Figure 1 ), further aggravating the gaps in diagnostic networks with issues related to coverage and reliability of testing. More than 48.0% of countries have gaps in defining or providing access to tier-specific laboratory testing strategies, while more than 84.0% of the countries assessed demonstrated sustainable capacity for laboratory testing to support the surveillance of 10 priority diseases. The Global Health Security Agenda laboratory network (LABNET 26 ) scorecard was developed to complement the Joint External Evaluation tool and to provide more granularity on nine core capabilities of the laboratory network and systems, enabling the identification of specific gaps and related root causes. In eight countries where this evaluation was conducted, the average performance of laboratory networks ranged from none to basic capacity across the nine core capabilities assessed (Figure 2 ), highlighting the presence of many common disabling factors ( the needs of clinical diagnostics and disease surveillance is another important intervention with the potential to guide the introduction of diagnostics at the levels where they are most needed and cost-effective. We recommend that every country conduct an external or self-evaluation of their laboratory systems once a year or once every two years as part of a continuous quality improvement cycle for their national tiered laboratory network. While the Joint External Evaluation tool provides high-level dashboards for a set of four indicators, the LABNET scorecard is designed to guide countries in selecting specific and feasible interventions most likely to tackle the root causes of the identified dysfunctions across a comprehensive set of indicators.

Mutualising scarce resources for most cost-effective health services is (or should be) a constant concern in low-resource settings. A data-driven configuration of a Note: The eight countries were assessed across the following nine core capabilities: (1) policy, legal and regulatory framework, (2) structure of the laboratory network, (3) coverage and response, (4) laboratory information management system, (5) infrastructures, (6) workforce, (7) quality management system, (8) biosafety and biosecurity, (9) priority diseases. Addressing the common problem of fragmented and diseasespecific STSs, ASLM coordinated the development of a standardised STS assessment and development toolkit, 28 addressing multiple diseases, surveillance and clinical diagnostic needs, and factoring in different modes of transportation. One country, Burkina Faso, was able to use the findings of the assessment to establish a new specimen referral system for surveillance that is now being built upon, scaled up and integrated to cover any disease programme. 29 The availability of up-to-date geo-localised information about laboratory network capacity provides evidence on which to base the process of defining optimal service configurations, including the shortest routes for sample transportation, maximum population coverage for testing services, cost-effective supply chains, or opportunities for testing integration. Initiatives aimed at collecting geographical information system data on laboratory capacity are gaining momentum to improve the performance of HIV and tuberculosis control programmes. 30 33 ) and fostering country ownership. This system allows the easy collection, curation and analysis of geospatial data to make informed decisions on national laboratory networks and is interoperable with the District Health Information System (DHIS2, University of Oslo, Norway) 2 34 . Thirteen of the 54 countries on the continent (24%) are currently using the system under the coordination of Africa CDC's regional coordinating centres. 35 Among the 101 level 4 and level 3 laboratories assessed, only 40% had the capacity to conduct culture or polymerase chain reaction-based tuberculosis diagnosis, 11% and 34% could perform HIV drug resistance genotyping and early infant diagnosis, and 36% could run confirmatory testing for meningitis through culture or polymerase chain reaction ( Figure 3 ). Using LabMap data from 2018, we determined that in Niger, 36 eight facilities at level 3 are conducting meningitis testing, including serology, bacterial culture and nucleic acid testing, covering a total of 7.9 million people (40% of the Nigerien population) within a 2-hour drive radius. Only one facility (covering 2.8 million people, 14% of the population) is equipped to conduct polymerase chain reaction for the differential diagnosis of pathogens causing meningitis, which is critical for the swift adjustment of antibiotic therapy. PlanWise calculated that three strategically located level 3 laboratories involved in meningitis testing could be upgraded with a maximum impact reaching out to an additional 4.1 million (20%) inhabitants. PlanWise and other similar software like the Supply Chain Guru from Llamasoft 37 offer the opportunity to calculate the best options to improve the laboratory network testing capacity and coverage, including upgrading existing facilities, building new laboratories or configuring specimen referral and supply chain routes.

Data-driven optimisation of laboratory networks is an important management activity that can support essential public health and clinical functions. Key considerations of any optimisation exercise should include at least: the structure of the tiered laboratory networks, (essential) testing needs for both clinical diagnosis and disease surveillance, and opportunities for test integration. Specimen referrals are important systems underlying national laboratory networks. Taking a network approach EIA, enzyme immuno assay; PCR, polymerase chain reaction; RT-PCR, real-time polymerase chain reaction. for developing integrated STSs may provide greater cost savings, efficiencies, increased coverage and increased access. This approach can begin by mapping and optimising the overall referral network based on the existing diagnostics network (or any upcoming changes), reducing redundancies where possible and leveraging existing or new systems to create economies of scale, clearly planning and budgeting for the optimised network and implementing the new approach. Any potential benefits should be clearly estimated and used to convince governments of the approach and gain buy-in from other stakeholders as well.

Regular collection and updating of (geo-located) laboratory capacity information is necessary to inform network optimisation exercises. Such activities could be enforced as part of laboratory registration or licensing and re-licensing processes under the coordination of the directorate of laboratories.

Unreliable diagnostic tests can compromise the quality of healthcare delivery. A laboratory quality management system (LQMS) is a formalised system that documents processes, procedures and responsibilities for achieving an international standard of quality. The implementation of LQMS was identified as a priority to strengthen laboratory services in Africa 38,39 a decade ago. As part of this momentum effect, various tools and frameworks have been developed and disseminated to guide laboratories towards LQMS implementation and International Organization for Standardization 15189 accreditation. Some of these resources have a regional or a disease-specific focus; these include the Strengthening Laboratory Management Toward Accreditation, the Stepwise Laboratory Quality Improvement Process Towards Accreditation (SLIPTA), which also includes a tuberculosis-specific checklist, the LQMS training tool kit and the Laboratory Quality Services International group. To date, around 520 laboratories have received international accreditation on the continent. More than 370 of these accredited facilities are in South Africa and most of them belong to the public sector, highlighting geographic differences and the lagging behind of private laboratories. The SLIPTA is a WHO regional office for Africa programme assessing laboratory progress towards the International Organization for Standardization 15189 standards and with ASLM serving as the secretariat. Since its launch in 2012, around 430 laboratories implementing LQMS have been assessed across 17 countries (Table 2) , illustrating the increasing awareness of national stakeholders with regard to quality requirements, as well as the commitment of the laboratory community to advance diagnostic services. However, this number is below the original target of 2500 enrolled laboratories set at the programme onset 40 and represents a modest outcome at both the continental and country scale. A couple of countries have demonstrated impressive coverage of the SLIPTA programme (e.g. Botswana and Namibia, Table 2 ). However, assuming that only 50% of the total number of government laboratories are in hospitals (the target facilities to implement the International Organization for Standardization 15189 norm), the current number of laboratories engaged in SLIPTA represent only 0.3% of the total number of government laboratories in Nigeria and 3% in Kenya. Some bottlenecks with LQMS implementation using SLIPTA are inherent to the programme itself. The handling of certification requests and processes through countries' Ministry of Health prioritises government over private laboratories. The lack of core funding supporting the programme translates into insufficient capacity for ASLM to cover the needs of an entire continent, not only to conduct audits but also to mentor laboratories towards quality improvement and accreditation. Benefitting from more stable United States President's Emergency Plan for AIDS Relief funding, and despite reaching an impressive 1333 laboratories across various continents, 41 the mentorship-focused Strengthening Laboratory Management Toward Accreditation programme is equally unable to comprehensively cover the needs of entire national laboratory networks. Advocacy efforts towards policymakers are also impaired by the lack of simple indicators linking LQMS implementation with improved health outcomes. Countryspecific roadblocks have also been identified such as low political commitment and the lack of regulatory and policy frameworks guiding the expansion of LQMS as national programmes, adapted for each tier of laboratory networks. Recently, Continuous Quality Improvement initiatives targeting disease-specific testing (such as HIV) have been implemented. Although Continuous Quality Improvement directly addresses the quality of diagnostic testing through a problem-solving approach linked to patient outcomes, it still needs to be embedded into larger quality management programmes in order to contribute to sustainable outcomes supporting Universal Healthcare Coverage and International Health Regulations.

In addition to the poor coverage of LQMS implementation, most countries do not have systems in place to ensure that all testing sites comply with the basic components of quality assurance such as external quality assessments, proficiency testing schemes 42 and various quality checks linked to postmarket surveillance of IVD. Collectively, these observations suggest that dramatically high proportions of diagnostic tests delivered in African countries are not adequately quality assured. This inevitably results in laboratory test results that are incorrect or fraudulent, causing a lack of trust among clinicians and communities.

To overcome these challenges, the ASLM and WHO regional office for Africa launched SLIPTA version 2.0, 43 which proposes to institutionalise SLIPTA at the country level, harness partner resources for SLIPTA funding and redefine the role of ASLM as a coordinating rather than an implementing body.

This strategic approach is currently being implemented through regional collaborations where the West African Health Organization and East, Central and Southern Africa Health Community are providing leadership to advance LQMS using the SLIPTA programme in West, Central East and Southern Africa, with ASLM serving as a high-level coordinator. According to this model, ASLM and its partners work at generating a sufficient pool of local SLIPTA auditors and laboratory mentors who can be mobilised to advance LQMS and conduct SLIPTA audits upon regional or national request. The efforts of Africa CDC to establish The Regional Integrated Laboratory Network (RISLNET) is also contributing to the extension of SLIPTA version 2.0, through the implementation of LQMS in national public health institutes, with subsequent deployment of the system in lower tiers of the national laboratory networks and across the private sector.

A couple of African countries like Ethiopia have stepped forward to 'franchise' the SLIPTA model as national programmes aiming to cover all laboratory facilities from the public and the private sector. The foundation of a country-led SLIPTA programme is the definition of national quality standards for diagnostic services at each level of service delivery, clearly describing which laboratory has the vocation to be accredited or certified and against which set of minimum quality standards.

Clinical pathologists are physicians trained in various disciplines of laboratory medicine, such as haematology, medical microbiology, transfusion medicine, clinical biochemistry or cytopathology. 44 They provide highly specialised knowledge and leadership, ensuring the quality of the pre-analytical, analytical and post-analytical phases of testing, as well as critical information on the severity and prognosis of diseases based on test results. Clinical pathologists make sure that patients are started and maintained on the correct treatment regimen. In the United States and United Kingdom, the pathology workforce varies between 3 and 5 per 100 000 inhabitants. 45 46 although this profession requires a background in medical studies, suggesting insufficient clinical interpretation of laboratory test results that might compromise patient outcomes. Secondly, an up-to-date inventory of pathologists by national professional councils seems to be lacking in many countries, suggesting that these highly specialised professionals are not adequately registered or certified in their respective countries. Thirdly, the ratio of pathologists (regardless of their specialty) is 5-350 times lower than ratios observed in the United States (Table 3) , translating into gaps of more than 4000 pathologists for a country like Ethiopia or more than 6000 for a country like Nigeria. In most countries sampled, the number of pathologists is lower than the number of tier 2 and tier 3 hospitals (where pathology services are required), suggesting that clinical pathologists would have to serve in more than one facility to reduce the gaps. For example, 61 pathologists in Ethiopia have to support a total of 400 hospitals. The number of medical microbiologists (a sub-specialty of clinical pathology), at 0.5, is even lower in all countries sampled. This worrisome situation raises concerns about the sustainability and impact of current global and national efforts to establish diagnostic capacity for the control of antibiotic resistance on the African continent. The introduction of novel diagnostic technologies such as point-of-care testing at the community level or next generation sequencing at the reference level will only increase the need for specialised laboratory medicine professionals who are able to ensure the correct use and interpretation of diagnostic tests for improved patient and public health outcomes. Collectively, these data highlight severe gaps in general and clinical pathology, in particular in sub-Saharan African countries.

In-country capacity for pathology training is commonly reported, with efforts by the College of Pathologists in East, Central and Southern Central Africa and other organisations to advocate for training of more pathologists and the laboratory workforce. However, the magnitude of the gaps highlighted here and by others demands that many more resources be deployed to produce higher numbers of pathologists at a faster pace in the disciplines associated with the most severe disease burdens, and to provide acceptable solutions for task shifting at each tier of the laboratory network. Key interventions to reduce the shortage of clinical pathologists include: the formulation of staffing norms in national laboratory strategic plans and healthcare human resources development strategies by defining the number and profile of pathologists at each relevant tier of the laboratory network and increasing opportunities for education, training and mentorship at the regional level, including innovative digital, remote training options. This could be done as part of the objective of the Workforce Development Institute of Africa CDC, 47 with the establishment of certification and qualification programmes that ensure standard levels of competency, at least in national public health institutes.

The past decade has seen the introduction of game-changing technologies for major public health diseases such as HIV, tuberculosis and malaria, which promise easier access, use and impact of diagnostics at the community level where most patients seek care. The WHO's IVD prequalification process is a standardised procedure to determine whether products meet requirements for safety, quality and performance. The findings of this prequalification are used to provide guidance to countries in selecting laboratory diagnostics to be implemented at the programme level. The WHO prequalification represents the 'ticket' for any IVD to penetrate national markets, and is a process that takes 2-3 years. Additionally, national regulatory frameworks often foresee additional evaluations to verify that the prequalified diagnostic is adapted to specific contexts. However, the relevance of multiple, in-country evaluations is not always clear, represents unnecessary repetition, and has no additional value compared to WHO prequalification results or to a well-designed single evaluation conducted in one centre of excellence located in a region with similar disease epidemiology. Delayed registration of IVDs in-country prevents access to reliable existing diagnostics for many priority diseases including those associated with outbreaks. Regulatory bottlenecks for IVDs during country registration compromise the implementation of essential diagnostics, and prevent universal health coverage and African health security.

An innovative approach to facilitate the swift evaluation and registration of useful and performant IVD and support the advancement of the diagnostic agenda in African regions is needed. Leveraging existing networks of excellence that can quickly conduct the standardised evaluation of IVDs and support collaborative registration procedures on behalf of entire regions of Africa can lead to critical benefits in access to IVD, while waiting for or to complement WHO prequalification. The Africa Collaborative to Advance Diagnostics, led by Africa CDC, was launched in Abuja during the biannual ASLM conference in 2018 48 with the overall aim of advocating for appropriate investment in diagnostics as well as accelerating regulations to facilitate timely and wide access to essential diagnostics. One of the goals of the Africa Collaborative to Advance Diagnostics is to work towards speedier registration of diagnostic technologies, through a pan-African approach that complements WHO prequalification, leverages existing continental expertise and provides opportunities for manufacturers and other relevant stakeholders to support the process.

In addition to advancing the development of increasingly relevant, reliable, specific and affordable IVD products, the future of diagnostics in Africa also depends on our collective ability to comprehensively and swiftly address the systemic weaknesses in national laboratory networks. Under the leadership of the Africa CDC and WHO regional office for Africa, African technical agencies at the continental or regional level (e.g. ASLM, the West African Health Organization and East Central and Southern Africa Health Community) or national level (e.g. Nigeria CDC) have a critical role to play in providing direct technical assistance and vision for advancing national laboratory network diagnostic capacity and on setting adequate priorities for international cooperation. Implementing the African Union recommendations on domestic investment in healthcare 49 is critical to ensure that laboratory systems and networks are sustainably prepared for the future of diagnostics in Africa.

Laboratory medicine in Africa: A barrier to effective health care

Laboratory medicine in low-income and middle-income counrties: Progress and challenges

Improving access to new diagnostics through harmonized regulation: Priorities for action

World Health Organization HIV diagnostic test in low and middle income countries forecasts of global demand for

UNICEF and WHO urge countries in western and central Africa to step up the pace in the response to HIV for children and adolescent

Drug resistant tuberculosis in Africa: Current status, gaps and opportunities

A study to understand the underutilization of Laboratory tests for antenatal care in Senegal

World health Organization Regional Office for Africa. Cervical cancer common amongst African women

Increasing the acceptability of HIV counseling and testing with three C's: Convenience, confidentiality and credibility

Rapid diagnostic test for malaria

Impact of HbA1c testing at point of care on diabetes management

Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children

Evaluation of a routine point-of-care intervention for early infant diagnosis of HIV: An observational study in eight African countries

Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: Individual patient data meta-analysis

Improving prescribing practices with rapid diagnostic tests (RDTs): Synthesis of 10 studies to explore reasons for variation in malaria RDT uptake and adherence

Overcoming health systems barriers to successful malaria treatment

World Health Organization. Maputo Declaration

WHO African region: JEE mission reports

Readiness of sub-Saharan Africa healthcare systems for the new pandemic, diabetes: A systematic review

A heavy burden: The productivity cost of illnesses in Africa

Are post Ebola reconstruction efforts neglecting public health laboratory systems?

Joint external evaluation -Development and scale-up of global multisectoral health capacity evaluation process

A new matrix for scoring the functionality of national laboratory networks in Africa: Introducing the LABNET scorecard

World Health Organization methodology to prioritize emerging infectious diseases in need of research and development

GLI specimen referral toolkit

Designing and piloting the first sample referral system in Burkina Faso using the national postal service

Monitoring viral load for the last mile: What will it cost?

Optimizing viral load testing access for the last mile: Geospatial cost model for point of care instrument placement

Geographic optimization of health system coverage

COVID-19 surveillance package

Africa Centres for Disease Control and Prevention. Strategic Plan

Open spatial demographic data and research

World Health Organization Regional Committee for Africa. Resolution AFR/ RC58/R2 to strengthen public health laboratories in WHO African region at all levels of the healthcare system: a critical need for disease control

ASLM2020: Strategies and vision to strengthen Public Health Laboratory Medicine in Africa

Available from: www.slmta.org 42. Carter JY. External quality assessment in resource-limited countries

SLIPTA 2.0 -The next 'country driven' frontier for laboratory quality improvement

An essential pathology package for low and middle income countries

Pathologist workforce in the United States

Repenser la formation des biologistes. Le laboratoire en zone tropicale

Africa CDC Institute for Workforce Development

Africa Centres for Disease Control and Prevention and partners launch the Africa Collaborative Initiative to Advance Diagnostics -AFCAD to address existing barriers towards advancing the diagnostic agenda in Africa

Africa leadership meeting

The authors thank the African Society for Laboratory Medicine and the Africa Centres for Disease Control and Prevention team members Samba Diallo, Edwin Shumba and Anafi Mataka for their input in data collection and analysis. We thank Dr Kameko Nichols for her contribution to the section on sample transportation systems. We thank Dr Ali Elbireer for his contribution to the initial design of the manuscript. We thank Professor Oni Emmanuel Idigbe for his support in collecting data on African pathologists. We thank the Ministries of Health of Niger, Cameroon, Congo, Ethiopia, Democratic Republic of Congo, Chad, Zambia, Zimbabwe, Sao Tome and Principe, Gabon, Central African Republic and Malawi for sharing data on laboratory mapping.We thank the Ministries of Health of Ethiopia, Uganda, Burkina Faso, Senegal, Cameroon, Tanzania, Democratic Republic of Congo and Nigeria for sharing data on the LABNET scorecard assessment.

The authors declare that they have no conflicts of interest.

All authors contributed equally to the work.

Ethical approval is not required for this opinion article.

This work would not have been possible without funding from the Bill and Melinda Gates Foundation, the President Emergency Plan for AIDS Relief, The Global Health Security Agenda, UNITAID and Vital Strategies.

Data sharing is not applicable to this article as no new data were created or analysed in this study.

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors.